Literature DB >> 28258502

The value of the new scoring system for predicting neoplastic pericarditis in the patients with large pericardial effusion.

M Szturmowicz1, A Pawlak-Cieślik2, A Fijałkowska3, J Gątarek4, A Skoczylas5, M Dybowska6, K Błasińska-Przerwa7, R Langfort8, W Tomkowski6.   

Abstract

PURPOSE: Early recognition of neoplastic pericarditis (npe) is crucial for the planning of subsequent therapy. The aim of the present study was to construct the scoring system assessing the probability of npe, in the patients requiring pericardial fluid (pf) drainage due to large pericardial effusion.
METHODS: One hundred forty-six patients, 74 males and 72 females, entered the study. Npe based on positive pf cytology and/or pericardial biopsy specimen was recognised in 66 patients, non-npe in 80. Original scoring system was constructed based on parameters with the highest diagnostic value: mediastinal lymphadenopathy on chest CT scan, increased concentration of tumour markers (cytokeratin 19 fragments-Cyfra 21-1 and carcinoembryonic antigen-CEA) in pf, bloody character of pf, signs of imminent cardiac tamponade on echocardiography and tachycardia exceeding 90 beats/min on ECG. Each parameter was scored with positive or negative points depending on the positive and negative predictive values (PPV, NPV).
RESULTS: The area under curve (AUC) for the scoring system was 0.926 (95%CI 0.852-0.963) and it was higher than AUC for Cyfra 21-1 0.789 (95%CI 0.684-0.893) or CEA 0.758 (95%CI 0.652-0.864). The score optimally discriminating between npe and non-npe was 0 points (sensitivity 0.84, specificity 0.91, PPV 0.9, NPV 0.85).
CONCLUSION: Despite chest CT and tumour marker evaluation in pericardial fluid were good discriminators between npe and non-npe, the applied scoring system further improved the predicting of neoplastic disease in the studied population.

Entities:  

Keywords:  Carcinoembryonic antigen; Chest computed tomography; Cytokeratins; Neoplastic; Pericardial fluid drainage; Pericarditis; Scoring system

Mesh:

Substances:

Year:  2017        PMID: 28258502     DOI: 10.1007/s00520-017-3645-4

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  23 in total

1.  CT findings in patients with pericardial effusion: differentiation of malignant and benign disease.

Authors:  Joo Sung Sun; Kyung Joo Park; Doo Kyoung Kang
Journal:  AJR Am J Roentgenol       Date:  2010-06       Impact factor: 3.959

2.  The role of early contrast-enhanced chest computed tomography in the aetiological diagnosis of patients presenting with cardiac tamponade or large pericardial effusion.

Authors:  Stefano Maggiolini; Caterina C De Carlini; Luca A Ferri; Gualtiero I Colombo; Gaetano Gentile; Ester Meles; Beatrice Riva; Teresa C Casella; Massimo Imazio; Antonio Brucato
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-09-15       Impact factor: 6.875

3.  Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results.

Authors:  L Antonangelo; R K Sales; A P Corá; M M P Acencio; L R Teixeira; F S Vargas
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

4.  Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion.

Authors:  Konstantinos Karatolios; Sabine Pankuweit; Bernhard Maisch
Journal:  Heart Fail Rev       Date:  2013-05       Impact factor: 4.214

5.  Frequency of recurrence of pericardial tamponade in patients with extended versus nonextended pericardial catheter drainage.

Authors:  Asim M Rafique; Nimish Patel; Simon Biner; Shervin Eshaghian; Fernando Mendoza; Bojan Cercek; Robert J Siegel
Journal:  Am J Cardiol       Date:  2011-09-10       Impact factor: 2.778

6.  Contemporary evaluation of the causes of cardiac tamponade: Acute and long-term outcomes.

Authors:  Ady Orbach; Jorge E Schliamser; Moshe Y Flugelman; Barak Zafrir
Journal:  Cardiol J       Date:  2015-07-23       Impact factor: 2.737

7.  2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).

Authors:  Yehuda Adler; Philippe Charron; Massimo Imazio; Luigi Badano; Gonzalo Barón-Esquivias; Jan Bogaert; Antonio Brucato; Pascal Gueret; Karin Klingel; Christos Lionis; Bernhard Maisch; Bongani Mayosi; Alain Pavie; Arsen D Ristic; Manel Sabaté Tenas; Petar Seferovic; Karl Swedberg; Witold Tomkowski
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

8.  Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade.

Authors:  Witold Zbyszek Tomkowski; Joanna Wiśniewska; Monika Szturmowicz; Paweł Kuca; Janusz Burakowski; Jarosław Kober; Anna Fijałkowska
Journal:  Support Care Cancer       Date:  2003-09-23       Impact factor: 3.603

Review 9.  Malignant pericardial effusion.

Authors:  I Burazor; M Imazio; G Markel; Y Adler
Journal:  Cardiology       Date:  2013-04-05       Impact factor: 1.869

10.  Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion.

Authors:  Gianmauro Numico; Antonella Cristofano; Marcella Occelli; Marco Sicuro; Alessandro Mozzicafreddo; Elena Fea; Ida Colantonio; Marco Merlano; Pierluigi Piovano; Nicola Silvestris
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.